169 related articles for article (PubMed ID: 30677225)
1. Developing a New qPCR-Based System for Screening Mutation.
Zhu J; Zhao Y; Liu M; Gonzalez-Rivas D; Xu X; Cai W; Qi H; Dai L; Wang Z; Song X; Jiang G; Yang Y
Small; 2019 Mar; 15(9):e1805285. PubMed ID: 30677225
[TBL] [Abstract][Full Text] [Related]
2. Next-Generation Sequencing for Genotyping of Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration Samples in Lung Cancer.
Xie F; Zheng X; Mao X; Zhao R; Ye J; Zhang Y; Sun J
Ann Thorac Surg; 2019 Jul; 108(1):219-226. PubMed ID: 30885850
[TBL] [Abstract][Full Text] [Related]
3. Comparison of targeted next-generation sequencing (NGS) and real-time PCR in the detection of EGFR, KRAS, and BRAF mutations on formalin-fixed, paraffin-embedded tumor material of non-small cell lung carcinoma-superiority of NGS.
Tuononen K; Mäki-Nevala S; Sarhadi VK; Wirtanen A; Rönty M; Salmenkivi K; Andrews JM; Telaranta-Keerie AI; Hannula S; Lagström S; Ellonen P; Knuuttila A; Knuutila S
Genes Chromosomes Cancer; 2013 May; 52(5):503-11. PubMed ID: 23362162
[TBL] [Abstract][Full Text] [Related]
4. Somatic mutations and immune checkpoint biomarkers.
Parris BA; Shaw E; Pang B; Soong R; Fong K; Soo RA
Respirology; 2019 Mar; 24(3):215-226. PubMed ID: 30636374
[TBL] [Abstract][Full Text] [Related]
5. Comparison of Next-Generation Sequencing, Quantitative PCR, and Sanger Sequencing for Mutation Profiling of EGFR, KRAS, PIK3CA and BRAF in Clinical Lung Tumors.
Gao J; Wu H; Shi X; Huo Z; Zhang J; Liang Z
Clin Lab; 2016; 62(4):689-96. PubMed ID: 27215089
[TBL] [Abstract][Full Text] [Related]
6. A comprehensive analysis of clinical outcomes in lung cancer patients harboring a MET exon 14 skipping mutation compared to other driver mutations in an East Asian population.
Gow CH; Hsieh MS; Wu SG; Shih JY
Lung Cancer; 2017 Jan; 103():82-89. PubMed ID: 28024701
[TBL] [Abstract][Full Text] [Related]
7. Yield of Malignant Pleural Effusion for Detection of Oncogenic Driver Mutations in Lung Adenocarcinoma.
DeMaio A; Clarke JM; Dash R; Sebastian S; Wahidi MM; Shofer SL; Cheng GZ; Li X; Wang X; Mahmood K
J Bronchology Interv Pulmonol; 2019 Apr; 26(2):96-101. PubMed ID: 30048416
[TBL] [Abstract][Full Text] [Related]
8. ALK and ROS1 rearrangement tested by ARMS-PCR in non-small-cell lung cancer patients via cytology specimens: The experience of Shanghai Pulmonary Hospital.
Cao Z; Wu W; Zhang W; Li Z; Gao C; Huang Y; Zhang L
Diagn Cytopathol; 2020 Jun; 48(6):524-530. PubMed ID: 32150350
[TBL] [Abstract][Full Text] [Related]
9. Next generation MUT-MAP, a high-sensitivity high-throughput microfluidics chip-based mutation analysis panel.
Schleifman EB; Tam R; Patel R; Tsan A; Sumiyoshi T; Fu L; Desai R; Schoenbrunner N; Myers TW; Bauer K; Smith E; Raja R
PLoS One; 2014; 9(3):e90761. PubMed ID: 24658394
[TBL] [Abstract][Full Text] [Related]
10. Predictive value of oncogenic driver subtype, programmed death-1 ligand (PD-L1) score, and smoking status on the efficacy of PD-1/PD-L1 inhibitors in patients with oncogene-driven non-small cell lung cancer.
Ng TL; Liu Y; Dimou A; Patil T; Aisner DL; Dong Z; Jiang T; Su C; Wu C; Ren S; Zhou C; Camidge DR
Cancer; 2019 Apr; 125(7):1038-1049. PubMed ID: 30548240
[TBL] [Abstract][Full Text] [Related]
11. Unique prevalence of oncogenic genetic alterations in young patients with lung adenocarcinoma.
Tanaka K; Hida T; Oya Y; Yoshida T; Shimizu J; Mizuno T; Kuroda H; Sakakura N; Yoshimura K; Horio Y; Sakao Y; Yatabe Y
Cancer; 2017 May; 123(10):1731-1740. PubMed ID: 28177518
[TBL] [Abstract][Full Text] [Related]
12. Epidermal Growth Factor Receptor (EGFR) Mutations and Anaplastic Lymphoma Kinase/Oncogene or C-Ros Oncogene 1 (ALK/ROS1) Fusions Inflict Non-Small Cell Lung Cancer (NSCLC) Female Patients Older Than 60 Years of Age.
Ke L; Xu M; Jiang X; Sun X
Med Sci Monit; 2018 Dec; 24():9364-9369. PubMed ID: 30580372
[TBL] [Abstract][Full Text] [Related]
13. ALK, ROS1 and RET fusions in 1139 lung adenocarcinomas: a comprehensive study of common and fusion pattern-specific clinicopathologic, histologic and cytologic features.
Pan Y; Zhang Y; Li Y; Hu H; Wang L; Li H; Wang R; Ye T; Luo X; Zhang Y; Li B; Cai D; Shen L; Sun Y; Chen H
Lung Cancer; 2014 May; 84(2):121-6. PubMed ID: 24629636
[TBL] [Abstract][Full Text] [Related]
14. Performance of amplicon-based next generation DNA sequencing for diagnostic gene mutation profiling in oncopathology.
Sie D; Snijders PJ; Meijer GA; Doeleman MW; van Moorsel MI; van Essen HF; Eijk PP; Grünberg K; van Grieken NC; Thunnissen E; Verheul HM; Smit EF; Ylstra B; Heideman DA
Cell Oncol (Dordr); 2014 Oct; 37(5):353-61. PubMed ID: 25209392
[TBL] [Abstract][Full Text] [Related]
15. Updated guidelines for predictive biomarker testing in advanced non-small-cell lung cancer: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology.
Garrido P; Conde E; de Castro J; Gómez-Román JJ; Felip E; Pijuan L; Isla D; Sanz J; Paz-Ares L; López-Ríos F
Clin Transl Oncol; 2020 Jul; 22(7):989-1003. PubMed ID: 31598903
[TBL] [Abstract][Full Text] [Related]
16. Comparison of targeted next-generation sequencing with conventional sequencing for predicting the responsiveness to epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) therapy in never-smokers with lung adenocarcinoma.
Han JY; Kim SH; Lee YS; Lee SY; Hwang JA; Kim JY; Yoon SJ; Lee GK
Lung Cancer; 2014 Aug; 85(2):161-7. PubMed ID: 24857785
[TBL] [Abstract][Full Text] [Related]
17. Next‑generation sequencing‑based detection of EGFR, KRAS, BRAF, NRAS, PIK3CA, Her‑2 and TP53 mutations in patients with non‑small cell lung cancer.
Jing C; Mao X; Wang Z; Sun K; Ma R; Wu J; Cao H
Mol Med Rep; 2018 Aug; 18(2):2191-2197. PubMed ID: 29956783
[TBL] [Abstract][Full Text] [Related]
18. Going beyond EGFR.
Zimmermann S; Peters S
Ann Oncol; 2012 Sep; 23 Suppl 10():x197-203. PubMed ID: 22987962
[TBL] [Abstract][Full Text] [Related]
19. Multigene Combined Detection by RT-qPCR Using Cytological Specimens.
Ma Y; Zhao J; Du Y; Wang R; Ji X; Wu J; Guo X; Liu Y; Zhang Y
Acta Cytol; 2021; 65(5):393-402. PubMed ID: 34343999
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of Pemetrexed-Based Chemotherapy in Patients with ROS1 Fusion-Positive Lung Adenocarcinoma Compared with in Patients Harboring Other Driver Mutations in East Asian Populations.
Chen YF; Hsieh MS; Wu SG; Chang YL; Yu CJ; Yang JC; Yang PC; Shih JY
J Thorac Oncol; 2016 Jul; 11(7):1140-52. PubMed ID: 27094798
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]